|
20 May 2022 |
Cadherin 17-Targeted Novel Drug Modalities: a Target and Pipeline Review
|
|
19 May 2022 |
Almirall and Evotec enter into a multi-target alliance in Medical Dermatology
|
|
18 May 2022 |
BGF, Scottish National Investment Bank and Scottish Enterprise join forces to invest £8m in Aberdeen biologics company Elasmogen
|
|
17 May 2022 |
LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2
|
|
16 May 2022 |
AbbVie and Cugene Announce Collaboration in Autoimmune Diseases
|
|
13 May 2022 |
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology
|
|
12 May 2022 |
Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
|
|
11 May 2022 |
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
|
|
10 May 2022 |
Pfizer to Acquire Biohaven Pharmaceuticals
|
|
09 May 2022 |
Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Astellas for Antibodies to Reduce Tumor Microenvironment-Mediated Immunosuppression
|
|
09 May 2022 |
OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases
|
|
04 May 2022 |
Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
|
|
04 May 2022 |
Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
|
|
02 May 2022 |
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
|
|
01 May 2022 |
Abbvie and Plexium Enter into Multi-target Strategic Collaboration to Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions
|
|
01 May 2022 |
Biocytogen Enters into Antibody Agreement with Merck KGaA, Darmstadt, Germany
|
|
26 Apr 2022 |
Update on Regulatory Submission for Aducanumab in the European Union
|
|
20 Apr 2022 |
VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders
|
|
20 Apr 2022 |
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
|
|
19 Apr 2022 |
Biocytogen Enters Agreement With CtM Bio to Co-develop TCR-Mimic Antibody-Based Multi-Specific T cell Engagers
|
|
14 Apr 2022 |
Ubix Therapeutics, SK Biopharmaceuticals enter into research collaboration agreement to develop novel therapeutics based on targeted protein degradation
|
|
13 Apr 2022 |
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
|
|
13 Apr 2022 |
Engitix Announces Expanded Collaboration and Licensing Agreement with Takeda to Develop New Anti-Fibrotic Therapies in Inflammatory Bowel Disease
|
|
13 Apr 2022 |
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
|
|
13 Apr 2022 |
Autigen Announces Collaboration with Boehringer Ingelheim to Discover and Develop Novel Treatments for Hearing Loss
|
